Roche on Monday said it will buy Spark Therapeutics in a transaction valued at $4.3 billion as the Swiss drugmaker builds its hemophilia portfolio and seeks to keep pace in gene therapy with rivals like Novartis.
from Deals and IPOs https://ift.tt/2SZhKzK
No comments:
Post a Comment